Dehydroepiandrosterone for the treatment of systemic lupus erythematosus

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 1, 2002, Pages 23-31

  van Vollenhoven, Ronald F ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dehydroepiandrosterone; Systemic lupus erythematosus; Treatment

Indexed keywords

ANDROGEN; BENZOYL PEROXIDE; CORTICOSTEROID; CYTOKINE; ESTROGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; PLACEBO; PRASTERONE; PREDNISONE;

ACNE; ANIMAL EXPERIMENT; ANIMAL MODEL; ASTHMA; AUTOIMMUNE DISEASE; CLINICAL OBSERVATION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENDOCRINOLOGY; FOLLOW UP; GENDER; HEMATOLOGIC DISEASE; HIRSUTISM; HUMAN; IMMUNOMODULATION; LIPID ANALYSIS; LIVER DISEASE; MENSTRUATION DISORDER; MOUSE; NONHUMAN; OSTEOPOROSIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ACNE VULGARIS; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CLINICAL TRIALS; COGNITION; DEHYDROEPIANDROSTERONE; FEMALE; HIRSUTISM; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; TREATMENT OUTCOME;

EID: 0036314166     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.1.23     Document Type: Review

References (42)

1. Control of adrenal androgen secretion
2. Metabolism of dehydroepiandrosterone
3. Physiological importance of dehydroepiandrosterone
4. Regulation of murine lymphokine production in vivo. II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells
5. Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function
6. Natural regulators of T-cell lymphokine production in vivo
7. Dehydroepiandrosterone enhances IL-2 production and cytotoxic effector function of human T cells
8. Estrogen, progesterone, and testosterone: Can they be used to treat autoimmune diseases?
9. Gender and age in lupus
10. SLE and Klinefelter's syndrome
11. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience
12. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus
13. Alterations of estrogen metabolism in systemic lupus erythematosus
14. Increased oxidation of testosterone in systemic lupus erythematosus
15. Low plasma androgens in women with active or quiescent systemic lupus erythematosus
16. Low plasma androgens in women with systemic lupus erythematosus
17. Androgenic hormones modulate autoantibody responses and improve survival in murine lupus
18. Preliminary observations on danazol therapy of systemic lupus erythematosus: Effects on DNA antibodies, thrombocytopenia and complement
19. Danazol therapy in systemic lupus erythematosus. A one-year prospective controlled trial on 40 female patients
20. Experience with 19-nortestosterone in the therapy of systemic lupus erythematosus: Worsened disease after treatment with 19-nortestosterone in men and lack of improving women
21. Defective production of interleukin-1 and interleukin-2 in patients with systemic lupus erythematosus (SLE)
22. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus
23. Modulating the Th1/Th2 balance in inflammatory arthritis
24. Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes from patients with systemic lupus erythematosus (SLE)
25. Prevention of autoantibody formation and prolonged survival in new Zealand Black/New Zealand White F1 mice fed dehydroisoandrosterone
26. Dehydroisoandrosterone prevention of autoimmune disease in NZB/W F1 mice: Lack of an effect on associated immunological abnormalities
27. Studies of the treatment of nephritis in NZB/NZW mice with dehydroepiandrosterone
28. Dehydroepiandrosterone in systemic lupus erythematosus: Results of a double-blinded, placebo-controlled, randomized clinical trial
29. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus
30. Results of the GL701 (DHEA) multicenter steroid-sparing SLE study
31. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months
32. Dehydroepiandrosterone in systemic lupus erythematosus: Relationship between dosage, serum levels, and clinical response
33. Dehydroepiandrosterone (DHEA) treatment of depression
34. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women
35. Quality control of dehydroepiandrosterone dietary supplement products
36. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use
37. GL701 (prasterone, dehydroepiandrosterone) improves systemic lupus erythematosus
38. Improvement in bone mineral density in steroid-treated SLE patients during treatment with GL701 (GL701 (prasterone, dehydroepiandrosterone)
39. GL701 (prasterone, dehydroepiandrosterone) significantly reduces flares in female patients with mild to moderate systemic lupus erythematosus (SLE)
40. Dehydroepiandrosterone replacement in women with adrenal insufficiency
41. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial
42. The actions of exogenous dehydroepiandrosterone in experimental animals and humans